Australia Respiratory Devices Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook 2026-2030

The Australian respiratory devices market covers equipment used to treat, monitor, and diagnose chronic and acute respiratory conditions, including ventilators, CPAP/BiPAP machines, nebulizers, oxygen concentrators, spirometers, and associated consumables. Demand is anchored in a healthcare system that combines public hospital funding through Medicare and private insurance, with growing out-of-hospital and home-based care. The market is valued at approximately USD 0.385 billion in 2025 and is expanding at about 6.53% annually, broadly in line with regional Asia-Pacific patterns where aging populations and chronic disease burden are reshaping device demand.

• •Market size: ~USD 0.385 billion in 2025, with a 6.53% CAGR.
• •Product scope spans therapeutic, diagnostic, monitoring, and disposable devices.
• •End users include public and private hospitals, sleep clinics, and a fast-growing home-care segment.

Australia's aging demographic is a primary structural driver, as older adults are more prone to COPD, sleep apnea, and chronic respiratory failure requiring long-term device support. Rising prevalence of asthma, COPD, obstructive sleep apnea, and post-viral lung complications is increasing both acute and chronic demand for ventilators, CPAP/BPAP machines, and home oxygen systems. Government funding for chronic disease management, reimbursement pathways through private health insurers, and rapid adoption of telehealth and remote patient monitoring are accelerating device uptake outside hospital settings.

• •Aging population and chronic respiratory disease prevalence.
• •Public reimbursement and private insurance coverage of respiratory care.
• •Telehealth expansion enabling remote monitoring and home-based respiratory therapy.

The market is commonly segmented by product into therapeutic devices (ventilators, CPAP/BiPAP, nebulizers, oxygen concentrators), monitoring and diagnostic devices (spirometers, pulse oximeters, capnographs), and consumables such as masks, filters, and tubing. By disease indication, asthma, COPD, and sleep apnea account for the bulk of demand, with sleep apnea therapy growing particularly quickly as diagnosis rates rise. Within Australia, New South Wales and Victoria represent the largest state markets due to population size, while Queensland, Western Australia, and South Australia are growing steadily alongside regional hospital investment and home-care programs.

• •Therapeutic devices (CPAP, ventilators, oxygen) dominate revenue.
• •Sleep apnea and COPD are the fastest-growing disease segments.
• •Urban states (NSW, Victoria) lead consumption, with regional catch-up driven by home-care expansion.

What are the recent trends and outlook?

The most visible trend is digitalization, with smart inhalers, connected CPAP devices, Bluetooth-enabled pulse oximeters, and cloud-linked ventilators becoming mainstream in both clinical and home-care settings. Portable, battery-powered, and quieter devices are gaining share as patients and clinicians prioritize mobility and quality of life. Looking ahead, the market is expected to continue mid-single-digit annual growth through the late 2020s, with home-care, sleep apnea management, and digital respiratory therapeutics contributing the largest incremental gains.

• •Strong shift toward digital, connected, and remote-monitoring-enabled respiratory devices.
• •Home-care and sleep apnea therapy are the highest-growth segments within the market.
• •Continued mid-single-digit annual growth expected, supported by demographics and digital health adoption.